Yu Yunlong's introduction

Yu Yunlong? Yu Yunlong, an oncologist in the First Affiliated Hospital of Harbin Medical University, is a famous oncologist and vice chairman of the Cancer Society of Beijing Medical Association; Member of Asian Society of Clinical Oncology; Yu Yunlong, deputy chief physician, graduated from Dalian Medical University 1992, and has been engaged in tumor treatment for 26 years. He studied under Yang Haishan, a famous oncologist, and successively served as director of radiology department of Yanji Hospital, deputy chief physician of oncology department of the First Affiliated Hospital of Harbin Medical University, and deputy chief physician of oncology department of Beijing 30 1 Hospital. 1996- 1997 is a visiting scholar in pulmonary hospital, West Berlin. In 2006, he was the first batch of outstanding experts in Jilin Province, and was promoted to professor in 2007. Participated in molecular biomedical research on tumor targeting of digestive system in Beijing Sino-Japanese Friendship Hospital and Beijing 30 1 Hospital. Led the team to establish the first real multidisciplinary comprehensive treatment standard for gastric malignant tumor, and participated in the standardization construction of multidisciplinary comprehensive treatment for tumor. He presided over and participated in the 2 1 clinical and basic research project of digestive tract tumors. Obtained the research fund of Chinese Medical Association Foundation (CMB) and participated in the research of gastric cancer-specific gene expression profile in Stanford University. At the same time, he established and improved the tumor tissue specimen bank, specimen collection and management norms. In recent years, he has focused on the prevention and research of advanced metastatic malignant tumors, and is good at first aid for patients with severe tumors, protecting adrenal function and bone marrow function of tumor patients, and preventing bone marrow suppression, liver and kidney failure, etc. He has rich experience in medical adjuvant radiotherapy, chemotherapy application, conservative treatment and palliative treatment. Gastric cancer, pelvic cancer, renal cancer, intestinal cancer, gallbladder cancer, esophageal cancer, lung cancer, bladder cancer, etc. Actively promote standardized treatment and open up the field of conservative treatment of gastric cancer in China. The research direction mainly focuses on the clinical comprehensive treatment and mechanism of digestive system tumors. In recent years, he is mainly committed to improving the five-year survival rate of cancer, and is good at solving cancer pain, bone marrow suppression, intestinal obstruction, jaundice, liver and kidney failure and so on. It advocates the principle of painless treatment of advanced malignant tumors, and the operation should be considered after the huge tumors in the early and middle stages are reduced.